Cardiologist
Philippe Debonnaire (MD, PhD, FESC) graduated as cardiologist and obtained a Masters degree in Sports Medicine, both at Leuven University (Belgium).
Subsequently, he obtained a PhD, based on non-invasive cardiac imaging research at Leiden University Medical Hospital (the Netherlands).
Since 2013 he works as cardiologist (interventional echocardiographist) in Sint-Jan Hospital Bruges (Belgium) with clinical and scientific focus on (advanced) echocardiographic techniques (3D, strain, stress, TOE).
Apart from valvular and structural heart disease, his current focus includes cardiac amyloidosis, with ongoing publications and lecturing on (inter)national podia.
He is immediate BWGNICI past-president, current EACVI Scientific Committee board member (former EACVI HIT and Education Committee positions), responsible for the echocardiography imaging fellowship in his centre.
Speaker/consultancy fee: AstraZeneca, Alnylam, Bayer, Pfizer
Advisory board: AstraZeneca, Alnylam, Bayer, Pfizer
Amyloid research grants: AstraZeneca, Pfizer
PI amyloid (randomised controlled) trials and studies: Alexion – AstraZeneca Rare Disease, Alnylam, AstraZeneca, Bayer, BridgeBio, Bruges Cardiac Amyloidosis Registry, Eidos, ICAR, Intellia Therapeutics, Ionis, Novo Nordisk